NLS Pharmaceutics AG
NASDAQ:NLSP
0.1352 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.011 | 0.011 | 0.01 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.011 | -0.011 | -0.01 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 5.908 | 8.977 | 5.919 | 0.1 | 1.702 | 1.437 | 4.325 |
| General & Administrative Expenses
| 5.899 | 0.007 | 0.006 | 0.002 | 3.299 | 2.012 | 1.442 |
| Selling & Marketing Expenses
| -0.011 | 6.488 | 5.925 | 2.198 | 2.492 | 0 | 0 |
| SG&A
| 5.887 | 6.494 | 5.931 | 2.2 | 2.495 | 2.012 | 1.442 |
| Other Expenses
| 0 | 0.01 | -0.017 | -0.328 | 0 | -0.629 | 0 |
| Operating Expenses
| 11.796 | 15.471 | 11.851 | 2.299 | 4.197 | 3.449 | 5.767 |
| Operating Income
| -11.807 | -15.482 | -11.861 | -2.299 | -4.197 | -3.449 | -5.767 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.365 | -1.013 | -0.085 | -0.562 | -1.25 | -0.629 | -0.89 |
| Income Before Tax
| -12.172 | -16.496 | -11.946 | -2.861 | -5.447 | -5.147 | -6.657 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0.227 | -0.002 | -0.004 | 1.698 | -0.006 |
| Net Income
| -12.172 | -16.496 | -11.946 | -2.861 | -5.447 | -5.147 | -6.657 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| EPS Diluted
| -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| EBITDA
| -11.796 | -15.471 | -11.851 | -2.299 | -4.197 | -3.449 | -5.767 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |